Introduction: Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the
microtubule dynamics during cell cycle; this agent is currently available for previously …

Background: Vinflunine is a novel second generation of Vinca alkaloid. The binding of
vinflunine to tubulin and subsequent cellular arrest in mitosis is the core mechanism of this …

Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell
Lung Cancer Previously Treated With Page 1 Phase III Trial Comparing Vinflunine With …

A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent
vinflunine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated …

19033 Background: Single-agent vinflunine has activity in a variety of tumors. This Phase II
single-arm study was designed to evaluate the safety and efficacy of vinflunine given every 3 …

Objective: To review the pharmacology, pharmacokinetics, in vitro and in vivo efficacy, and
safety profile of vinflunine in the treatment of various solid tumors. Data sources: A literature …

7511 Background: Vinflunine (VFL) is a new microtubule inhibitor of the vinca alkaloid class
with clinical activity in NSCLC (J. Bennouna, BJC, 2006). Single-agent efficacy and safety of …

Introduction Vinflunine (Javlor) has shown significant antitumour activity in advanced non-
small cell lung cancer (NSCLC). We propose to define the recommended dose of vinflunine …

Background: Vinflunine is a novel microtubule inhibitor obtained by semi-synthesis using
superacidic chemistry to selectively modify the catharanthine moiety of Vinca alkaloid with …

Objective Vinflunine (VFL)(Javlor®), a novel fluorinated semisynthetic vinca alkaloid has
shown significant antitumor activity in advanced non-small cell lung cancer (NSCLC). We …